Heart Failure in Cardiac Amyloidosis
.png)
This Event Has Now Passed
Join us virtually for Heart Failure in Cardiac Amyloidosis: Suspecting and Diagnosing Transthyretin Amyloid Cardiomyopathy in Underdiagnosed Populations at Risk for Heart Failure on July 16, 2024 from 6:00 PM - 8:30 PM EDT / 5:00 PM - 7:30 PM CDT, to learn the signs and symptoms of heart failure in patients at risk for Cardiac Amyloidosis as well as the latest updates in diagnosis and treatment options.
Led by Program Chair, J. Clay Hays, Jr., MD, this program will focus on how to:
-
Recognize barriers to identification and diagnosis of ATTR-CM in patients at risk for Heart Failure.
-
Identify “Red Flags” and other markers of disease that raise suspicion and need for further testing.
-
Summarize the diagnostic evaluation for ATTR-CM including the differential diagnosis.
-
Demonstrate the importance of multimodality imaging in diagnosing ATTR-CM.
-
Discuss the importance of genetic testing and counseling.
-
Provide details of bone scintigraphy protocols and the importance of SPECT and SPECT/CT imaging, interpretation, and components of an appropriate report.
- Evaluate existing and new treatments for patients with ATTR-CM.
Program Format
Live, virtual session
Only registered participants will have access to view the session recording.
Registration
ASNC Members: Free
Non-Members: $25
Not yet a member? Join ASNC today and save!
Non-Members: $25
Not yet a member? Join ASNC today and save!
Who Should Attend?
You should attend this program if you are part of the multidisciplinary care team involved with cardiac amyloidosis patients; primary care, general cardiologists, heart failure specialists, nuclear cardiologists, multimodality imaging cardiologists, technologists, hematologists, neurologists, nurse practitioners, nurses, and physician assistants.
Credits
2.5* CME/CE credits
*Credits subject to change.
*Credits subject to change.
Program Chair
|
J. Clay Hays, Jr., MD |
Faculty
|
Sharmila Dorbala, MD, MPH, MASNC |
Tawfiq Al Lahham, MD |
Charles Moore, MD |
|
Pawel Pomianowski, MD |
Frederick Ruberg, MD |
Prem Soman, MD, PhD, MASNC |
Agenda
| Time in EDT | Faculty | |
| 6:00pm | Introduction – case presentation | J. Clay Hays, Jr., MD |
| 6:10pm | What is cardiac amyloidosis? | Frederick Ruberg, MD |
| 6:30pm | Amyloid mutations and role of genetic testing | Pawel Pomianowski, MD |
| 6:50pm | Polyneuropathy in amyloidosis | Tawfiq Al Lahham, MD |
| 7:10pm | Nuclear scintigraphy with bone avid tracers | Sharmila Dorbala, MD, MPH, MASNC |
| 7:30pm | Heart Failure management and supportive therapies | Charles Moore, MD |
| 7:50pm | Evolving therapeutic landscape in ATTR | Prem Soman, MD, PhD, MASNC |
| 8:10pm | Q&A | J. Clay Hays, Jr., MD |
| 8:30pm | Adjourn |
This program is supported by an unrestricted educational grant from Pfizer.